SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Papaioannou Andriana I, Fouka Evangelia, Tzanakis Nikolaos, Antoniou Katerina, Samitas Konstantinos, Zervas Eleftherios, Kostikas Konstantinos, Bartziokas Konstantinos, Porpodis Konstantinos, Papakosta Despoina, Tzouvelekis Argyris, Gerogianni Irini, Kotsiou Ourania, Makris Michael, Rovina Nikoletta, Vlachou Garyfallia, Markatos Miltiadis, Vittorakis Stelios, Katsoulis Konstantinos, Papanikolaou Ilias, Afthinos Andreas, Katsaounou Paraskevi, Steiropoulos Paschalis, Latsios Dimitrios, Dimakou Katerina, Koukidou Sofia, Hillas Georgios, Tryfon Stavros, Kallieri Maria, Georgopoulou Athina, Avarlis Pantelis, Bakakos Petros, Markopoulou Katerina, Gaki Eleni, Paspala Asimina, Kyriakaki Zacharoula, Gourgoulianis Konstantinos I, Papiris Spyridon, Loukides Stelios
Аннотация
OBJECTIVE: To prospectively observe a cohort of severe asthmatics treated with biologics for the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and disease severity during the COVID-19 pandemic.
METHODS: Physicians from centers treating patients with severe asthma all over Greece provided demographic and medical data regarding their patients treated with biologics. Physicians were also asked to follow up patients during the pandemic and to perform a polymerase chain reaction test in case of a suspected SARS-Cov-2 infection.
RESULTS: Among the 591 severe asthmatics (63.5% female) included in the study, 219 (37.1%) were treated with omalizumab, 358 (60.6%) with mepolizumab, and 14 (2.4%) with benralizumab. In total, 26 patients (4.4%) had a confirmed SARS-CoV-2 infection, 9 (34.6%) of whom were admitted to the hospital because of severe COVID-19, and 1 required mechanical ventilation and died 19 days after admission. Of the 26 infected patients, 5 (19.2%) experienced asthma control deterioration, characterized as exacerbation that required treatment with systemic corticosteroids. The scheduled administration of the biological therapy was performed timely in all patients with the exception of 2, in whom it was postponed for 1 week according to their doctors' suggestion.
CONCLUSION: Our study confirms that despite the initial concerns, SARS-CoV-2 infection is not more common in asthmatics treated with biologics compared with the general population, whereas the use of biologic treatments for severe asthma during the COVID-19 pandemic does not seem to be related to adverse outcomes from severe COVID-19.